Gustave Roussy Company Profile

03:02 EDT 18th June 2019 | BioPortfolio

News Articles [12 Associated News Articles listed on BioPortfolio]

XenTech SAS Partners with Gustave Roussy for Cancer

For the development of a collection of tumor explant models from patients who developed acquired resistance to targeted therapies following initial responses

Innovate Biopharmaceuticals Announces Collaboration with Institut Gustave Roussy to Study Regulation of Intestinal Permeability and the Gut Microbiota using Larazotide in Immuno-oncology Checkpoint Inhibitor Failure Pre-Clinical Models

RALEIGH, N.C., March 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...

Metastatic castration resistant prostate cancer: Updates from ASCO 2019

Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA), Dr Joaquin Mateo (Vall d'Hebron Institute of Oncology, Barcelona, Spain) and Dr Karim Fizazi (Institut Gustave Roussy, Paris, Fr...

Updates in the management of pancreatic cancer from ASCO 2019

Dr Ian Chau (The Royal Marsden Hospital, London, UK), Prof Michel Ducreux (Institut Gustave Roussy, Paris, France), Dr Vaihab Sahai (University of Michigan, Michigan, USA) discuss the latest updates f...

Gustave Roussy and Embleema Announce Healthcare Blockchain Initiative to Accelerate Cancer Research

Blockchain technology has the potential to improve transparency, trust, patient safety and patient engagement in oncology clinical trials Patien...

Protagen AG Appoints Immuno-Oncology Experts to Its Scientific Advisory Board

Protagen AG, a precision medicine specialist at the forefront of immuno-profiling, announced today the appointment of Immuno-Oncology experts PD Dr. Jessica Hassel (National Cente...

Israel’s Sheba Medical Center and International Research Partners Conquer New Cancer Frontier

Renowned for its collaborations with international partners in the advancement of medical innovation, Israel’s Sheba Medical Center, Tel HaShomer has surpassed another medical frontier, this time in...

PEP-Therapy Reports Positive Results From GLP-Toxicity Study of PEP-010 Drug Candidate

A major step towards clinical trials PEP-Therapy, a biotechnology company developing peptides as targeted therapies for oncology, announces that its first-in-class drug ...

Drugs and Medications [0 Results]


PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Management of locoregional recurrence after radical resection of a primary nonmetastatic retroperitoneal soft tissue sarcoma: The Gustave Roussy experience.

Despite surgery, many patients experience locoregional recurrence (LR), the optimum treatment of which is still debated.

Mutational screening of the SH3TC2 gene in Greek patients with suspected demyelinating recessive Charcot-Marie-Tooth disease reveals a varied and unusual phenotypic spectrum.

Charcot-Marie-Tooth disease type 4 C (CMT4C) is an autosomal recessive form of demyelinating peripheral neuropathy caused by mutations in SH3TC2, characterized by early onset, spine deformities and cr...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Video-Based Cognitive Behavioral Therapy for Insomnia in Adults Cancer Patients and Survivors

SLEEP-4-ALL-1 is a pilot and ecological study corresponding to the developpement phase of a randomized controlled multicentric trial SLEEP-4-ALL-2. The main objective of this second study ...

Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer

Merge the data of ultrasound with that of the anatomical and functional MRI is necessary since the high dose rate Curietherapy is carried out under ultrasound guidance. The investigators w...

Study to Validate a Model of Surgical Deescalation in Atypicals Breast Lesions

Routine screening mammography has increased the non-palpable suspicious lesion detection rate, requiring histopathological evaluation. The discovery of atypical lesions on the breast biops...

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer

This is a multicentre randomised double-blind phase II trial, sponsored by Gustave Roussy and involving one French center as well as the Spanish Lung Cancer Group (≈20 centers of the SLC...

Effects of Heart Rate Variability Biofeedback in Patients With Acute Ischemic Stroke

This explorative prospective study aims to assess the effects of heart rate variability biofeedback (HRV biofeedback) in patients with acute ischaemic stroke. Furthermore, the investigator...

Companies [4 Associated Companies listed on BioPortfolio]

Institut Gustave-Roussy

The Institute Gustave-Roussy is a non-profit private institution, exclusively devoted to oncology.It is part of the French public hospital system.State-approved, it is authorised to receive donations ...

Gustave Roussy

WIN Consortium

The WIN Consortium ( is a joint initiative of Institut Gustave Roussy (France) and University of Texas - MD Anderson Cancer Center (USA) which brings togethe...

Institut Gustave Roussy

The Institut Gustave Roussy (IGR, Villejuif, France), European leading Comprehensive Cancer Center, is a non profit academic entity belonging to the French public hospital service...

More Information about "Gustave Roussy" on BioPortfolio

We have published hundreds of Gustave Roussy news stories on BioPortfolio along with dozens of Gustave Roussy Clinical Trials and PubMed Articles about Gustave Roussy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Gustave Roussy Companies in our database. You can also find out about relevant Gustave Roussy Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record